Journal of Medical Cases, ISSN 1923-4155 print, 1923-4163 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Med Cases and Elmer Press Inc
Journal website http://www.journalmc.org

Case Report

Volume 11, Number 7, July 2020, pages 215-220

Therapeutic Challenges in Chronic Myeloid Leukemia: A Case-Based Discussion

Figures

Figure 1.
Figure 1. Percentage of p190 BCR-ABL1 via quantitative reverse transcription-polymerase chain reaction (qRT-PCR) over time according to TKI choices. TKI: tyrosine kinase inhibitor.
Figure 2.
Figure 2. Percentage of p210 BCR-ABL1 via quantitative reverse transcription-polymerase chain reaction (qRT-PCR) over time according to TKI choices. TKI: tyrosine kinase inhibitor.
Figure 3.
Figure 3. Percentage of p210 BCR-ABL1 via quantitative reverse transcription-polymerase chain reaction (qRT-PCR) over time according to TKI choices. TKI: tyrosine kinase inhibitor.